Mineralys doses first subject in Phase 3 Launch-HTN trial; topline data expected 2H 2025

Mineralys Therapeutics, Inc.

First subject dosed in Launch-HTN (NCT06153693), a global Phase 3 trial enrolling up to ~1,000 patients.
Trial evaluates lorundrostat as add-on for uncontrolled or resistant hypertension on 2-5 background drugs.
Three arms: placebo, lorundrostat 50 mg QD, or 50 mg titrated to 100 mg QD at week 6.
Primary endpoint: change in systolic BP vs placebo at 12 weeks by automated office measurement.
Topline data from Advance-HTN (first pivotal trial) expected in 2H 2024; Transform-HTN OLE ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.